Medical Condition News

RSS

Chemical properties of green tea benefit memory and spatial learning

It has long been believed that drinking green tea is good for the memory. Now researchers have discovered how the chemical properties of China's favorite drink affect the generation of brain cells, providing benefits for memory and spatial learning. The research is published in Molecular Nutrition & Food Research.

5 Sep 2012

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

Baxter International Inc. today announced that the company has submitted a biologics license application to the United States Food and Drug Administration for approval of BAX 326, a recombinant factor IX (rFIX) protein being investigated for the treatment and prophylaxis of bleeding episodes for patients over 12 years of age with hemophilia B.

From Baxter International Inc. 5 Sep 2012

Roadmap to areas of the brain associated with affective aggression

A North Carolina State University researcher has created a roadmap to areas of the brain associated with affective aggression in mice. This roadmap may be the first step toward finding therapies for humans suffering from affective aggression disorders that lead to impulsive violent acts.

5 Sep 2012

Regular Fanconi anemia cells aren't sensitive to resveratrol

Fanconi anemia is a recessive genetic disorder affecting 1 in 350,000 babies, which leaves cells unable to repair damaged DNA. This lack of repair puts Fanconi anemia patients at high risk for developing a variety of cancers, especially leukemias and head and neck cancer.

5 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults- glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour.

5 Sep 2012

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.

5 Sep 2012

AlloCure commences AC607 Phase 2 clinical trial for acute kidney injury

AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company's mesenchymal stem cell therapy, as a potential treatment for acute kidney injury.

5 Sep 2012

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

5 Sep 2012

EC grants European market authorization for Revestive to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the European Commission has granted European market authorization for the medicinal product teduglutide (trade name in Europe: Revestive) as a once-daily treatment for adult patients with short bowel syndrome.

5 Sep 2012

OptiMedica Catalys Precision Laser System for creating corneal incisions receives FDA 510(k) clearance

Global ophthalmic company OptiMedica Corp. has announced U.S. Food and Drug Administration 510(k) market clearance of its Catalys Precision Laser System for creating single-plane and multi-plane arc cuts/incisions in the cornea during cataract surgery.

5 Sep 2012

KYTHERA completes enrollment in ATX-101 Phase III trials for reduction of submental fat

KYTHERA Biopharmaceuticals, Inc. today announced the completion of enrollment in two pivotal U.S. and Canadian Phase III clinical trials of ATX-101, a potential first-in-class injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, which commonly presents as an undesirable "double chin." KYTHERA expects to release top-line results in mid-2013.

4 Sep 2012

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

BioLineRx Ltd., a biopharmaceutical drug development company, announced today that it has signed an exclusive, worldwide license agreement with Biokine Therapeutics Ltd., a Clal Biotechnology Industries portfolio company, for the development and commercialization of BL-8040 (formerly BKT-140), a Phase II ready drug candidate for the treatment of acute myeloid leukemia (AML), as well as other types of hematological cancer.

4 Sep 2012

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Pfizer Inc. announced today that the European Commission (EC) has granted marketing authorization for INLYTA (axitinib) for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

4 Sep 2012

Medical Condition News

Chemical properties of green tea benefit memory and spatial learning

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

Roadmap to areas of the brain associated with affective aggression

Regular Fanconi anemia cells aren't sensitive to resveratrol

FDA approves Bosulif to treat chronic myelogenous leukemia

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

AlloCure commences AC607 Phase 2 clinical trial for acute kidney injury

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

EC grants European market authorization for Revestive to treat short bowel syndrome

OptiMedica Catalys Precision Laser System for creating corneal incisions receives FDA 510(k) clearance

KYTHERA completes enrollment in ATX-101 Phase III trials for reduction of submental fat

Biokine, BioLineRx sign license agreement to develop and commercialize BL-8040 for AML

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Ultrastable RNA nanoparticles may help treat cancer and viral infections

Scientists discover new anti-cancer and anti-metastatic molecule

Meijer offers generic Lipitor for free to help families be heart healthy

A-kinase anchoring proteins influence levels of glucose in the body

GE Healthcare introduces KUBio factory

Study finds 93% reduction in head injuries related to cycling among Swedish children

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News